Company news

Inoviq Ltd news in 2022

Inoviq Ltd's news releases, calls and decks from 2022, newest first.

View company

Positive EXO-NET Results in Ovarian Cancer

December 12, 2022

MST Access Diagnostics Forum Presentation

December 4, 2022

CEO AGM Presentation

November 27, 2022

INOVIQ Settles Legal Proceedings

November 27, 2022

Commercial and R&D Update

November 24, 2022

Healthcare Conference Investor Presentation

November 10, 2022

IIQ Appendix 4C & Quarterly Activities Report-September 2022

October 27, 2022

Canadian Patent Granted for BARD1 Technology

October 27, 2022

Receipt of R&D Tax Incentive Refund

October 13, 2022

INOVIQ to Develop SubB2M-Based Test on Nicoya SPR Platform

October 12, 2022

2022 Annual Report and update on results

September 27, 2022

IIQ Investor Presentation

August 9, 2022

IIQ Appendix 4C & Quarterly Activities Report - June 2022

July 26, 2022

Positive SubB2M IHC Results for Melanoma

July 26, 2022

hTERT US Patent Granted

July 21, 2022

INOVIQ Engages Sales Team to Accelerate EXO-NET Roll-out

July 20, 2022

SubB2M US Patent Grant and Program Update

July 1, 2022

Australian Patent Granted for SubB2M Technology

May 2, 2022

INOVIQ Key Manufacturing Agreement to Advance SubB2M tests

May 1, 2022

IIQ Appendix 4C & Quarterly Activities Report - March 2022

April 29, 2022

INOVIQ Engages ResearchDX to Develop & Validate SubB2M-Tests

April 4, 2022

INOVIQ & UQ Collaborate on Exosome-based Ovarian Cancer Test

March 31, 2022

Update on Legal Proceedings and BARD1 Autoantibody Program

March 27, 2022

Brazilian Patent Issued for Lung & Colorectal Cancer

February 22, 2022

Appendix 4C & Quarterly Activities Report

January 30, 2022

Decks in 2022